# A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

> **NCT01614899** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 457 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SM-13496 40mg
- **DRUG:** SM-13496 80mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01614899
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-02
- **Primary completion:** 2014-11-17
- **Final completion:** 2014-11-17
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614899, "A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01614899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*